Summary
An immunotoxin consisting of ricin A chain linked to the monoclonal antibody M-T151, recognising the CD4 antigen, was weakly toxic to the human T-lymphoblastoid cell line CEM in tissue culture. The incorporation of [3H]leucine by CEM cells was inhibited by 50% at an M-T151-ricin-A-chain concentration (IC50) of 4.6 nM compared with an IC50 of 1.0 pM for ricin. In contrast, immunotoxins made by linking intact ricin to M-T151 in such a way that the galactose-binding sites of the B chain subunit were either blocked sterically by the antibody component or were left unblocked, were both powerfully cytotoxic with IC50 values of 20–30 pM. The addition of ricin B chain to CEM cells treated with M-T151—ricin-A-chain enhanced cytotoxicity by only eight-fold indicating that isolated B chain potentiated the action of the A chain less effectively than it did as an integral component of an intact ricin immunotoxin. Ricin B chain linked to goat anti-(mouse immunoglobulin) also potentiated weakly.
Lactose completely inhibited the ability of isolated ricin B chain to potentiate the cytotoxicity of M-T151—ricin-A-chain and partially (3- to 4-fold) inhibited the cytotoxicity of the blocked and non-blocked ricin immunotoxins. Thus, in this system, the galactose-binding sites of the B chain contributed to cell killing regardless of whether isolated B chain was associated with the A chain immunotoxin or was present in blocked or non-blocked form as part of an intact ricin immunotoxin. The findings suggest that the blocked ricin immunotoxin may become unblocked after binding to the target antigen to re-expose the cryptic galactose-binding sites. However, the unblocking cannot be complete because the maximal inhibition of [3H]leucine incorporation by the blocked immunotoxin was only 80% compared with greater than 99% inhibition by the non-blocked immunotoxin.
Similar content being viewed by others
References
Blakey DC, Wawrzynczak EJ, Wallace PM, Thorpe PE (1988) Antibody-toxin conjugates: a perspective. Prog Allergy 45: 50
Cumber AJ, Forrester JA, Foxwell BMJ, Ross WCJ, Thorpe PE (1985) The preparation of antibody-toxin conjugates. Methods Enzymol 112: 207
Esworthy RS, Neville DM Jr (1984) A comparative study of ricin and diphtheria toxin-antibody conjugate kinetics on protein synthesis inactivation. J Biol Chem 259: 11 496
Forrester JA, McIntosh DP, Cumber AJ, Parnell GD, Ross WCJ (1984) Delivery of ricin and abrin A chains to human carcinoma cells in culture following linkage to monoclonal antibody LICR-LOND-Fib75. Cancer Drug Deliv 1: 283
Frankel AE (ed) (1988) Immunotoxins. Kluwer Academic, Boston
Fulton RJ, Blakey DC, Knowles PP, Uhr JW, Thorpe PE, Vitetta ES (1986) Purification of ricin A1, A2 and B chains and characterization of their toxicity. J Biol Chem 261: 5314
Godal A, Fodstad O, Pihl A (1987) Studies on the mechanism of action of abrin-9.2.27 immunotoxin in human melanoma cell lines. Cancer Res 47: 6243
Gregg EO, Bridges SM, York RJ, Longo BL, Houston LL, Glennie MJ, Stevenson FK, Green I (1987) Whole ricin and recombinant ricin A chain idiotype-specific immunotoxins for therapy of guinea pig L2C B cell leukaemia. J Immunol 138: 4502
Knowles PP, Thorpe PE (1987) Purification of immunotoxins containing ricin A chain and abrin A chain using Blue Sepharose CL-6B. Anal Biochem 160: 440
Leonard JE, Wang Q, Kaplan NO, Royston I (1985) Kinetics of protein synthesis inactivation in human T lymphocytes by selective monoclonal antibody-ricin conjugates. Cancer Res 45: 5263
McIntosh DP, Edwards DC, Cumber AJ, Parnell GD, Dean CJ, Ross WCJ, Forrester JA (1983) Ricin B chain converts a non-cytotoxic antibody-ricin A chain conjugate into a potent and specific cytotoxic agent. FEBS Lett 164: 17
Nicolson GL, Blaustein J (1972) The interaction ofRicinus communis agglutinin with normal and tumour cell surfaces. Biochim Biophys Acta 266: 543
Preijers FWMB, De Witte T, Rijke-Schilder GPM, Tax WJM, Wessels JMC, Haanen C, Capel PJA (1988) Human T lymphocyte differentiation antigens as target for immunotoxins or complement-mediated cytotoxicity. Scand J Immunol 28: 185
Rieber P, Lohmeyer J, Schendel J, Gottlinger J, Brodmann S, Rank G, Heydecke S, Kopp E, Riethmuller G (1984) Characterisation of functional human T cell subsets by monoclonal antibodies. In: Bernard A, Boumsell L, Dausset J, Milstein C, Schlossman SF (eds) Leukocyte typing. Springer-Verlag, New York, p 303
Sattentau QJ, Dalgleish AG, Weiss RA, Beverley PCL (1986) Epitopes of the CD4 antigen and HIV infection. Science 234: 1120
Street NE, Fulton RJ, Sanders VM, Vitetta ES (1987) Inhibition of the helper function of murine T cells with Fab′-anti-L3T4 ricin A chain immunotoxin. J Immunol 139: 1734
Thorpe PE (1985) Antibody carriers of cytotoxic agents in cancer therapy: a review. In: Pinchera A, Doria G, Dammacca F, Bargellesi A (eds) Monoclonal antibodies '84. Biological and clinical applications. Editrice Kurtis, Milan, p 475
Thorpe PE, Ross WCJ (1982) The preparation and cytotoxic properties of antibody-toxin conjugates. Immunol Rev 62: 119
Thorpe PE, Brown ANF, Foxwell BMJ, Myers C (1983) Blockade of the galactose-binding site of ricin by its linkage to antibody. In: Boss BD, Langman R, Trowbridge I, Dulbecco R (eds) Monoclonal antibodies and cancer. Academic Press, New York, p 117
Thorpe PE, Ross WCJ, Brown ANF, Myers CD, Cumber AJ, Foxwell BMJ, Forrester JA (1984) Blockade of the galactose-binding sites of ricin by its linkage to antibody. Eur J Biochem 140: 63
Vitetta ES (1986) Synergy between immunotoxins prepared with native ricin A chains and chemically modified ricin B chains. J Immunol 136: 1880
Vitetta ES, Cushley W, Uhr JW (1983) Synergy of ricin A chaincontaining immunotoxins and ricin B chain-containing immunotoxins in in vitro killing of neoplastic human B cells. Proc Natl Acad Sci USA 80: 6332
Vitetta ES, Fulton RJ, Uhr JW (1984) Cytotoxicity of a cell-reactive immunotoxin containing ricin A chain is potentiated by an anti-immunotoxin containing ricin B chain. J Exp Med 160: 341
Vitetta EJ, Fulton RJ, May RD, Till M, Uhr JW (1987) Redesigning nature's poisons to create anti-tumour reagents. Science 238: 1098
Wawrzynczak EJ, Thorpe PE (1987) Methods for preparing immunotoxins: effect of the linkage on activity and stability. In: Vogel C-W (ed) Immunoconjugates: antibody conjugates in radioimaging and therapy of cancer. Oxford University Press, New York, p 28
Wawrzynczak EJ, Drake AF, Watson GJ, Thorpe PE, Vitetta ES (1988) Ricin B chain-containing immunotoxins prepared with heatdenatured B chain lacking galactose-binding ability potentiate the cytotoxicity of a cell-reactive ricin A chain immunotoxin. Biochim Biophys Acta 971: 55
Youle RJ, Neville DM Jr (1982) Kinetics of protein synthesis inactivation by ricin-anti-Thy1.1 monoclonal antibody hybrids. J Biol Chem 257: 1598
Youle RJ, Murray GJ, Neville DM Jr (1981) Studies on the galactose-binding site of ricin and the hybrid toxin Man6P-ricin. Cell 23: 551
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Wawrzynczak, E.J., Watson, G.J., Cumber, A.J. et al. Blocked and non-blocked ricin immunotoxins against the CD4 antigen exhibit higher cytotoxic potency than a ricin A chain immunotoxin potentiated with ricin B chain or with a ricin B chain immunotoxin. Cancer Immunol Immunother 32, 289–295 (1991). https://doi.org/10.1007/BF01789046
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01789046